US Patent Issued to BEIJING ZEQIN BIOMEDICAL on Aug. 11 for "Fusion peptide for treating autoimmune disease" (Chinese Inventors)

ALEXANDRIA, Va., Aug. 12 -- United States Patent no. 12,703,736, issued on Aug. 11, was assigned to BEIJING ZEQIN BIOMEDICAL Co. LTD (Beijing).

"Fusion peptide for treating autoimmune disease" was invented by Huawei Wei (Beijing) and Chenggang Yang (Beijing).

According to the abstract* released by the U.S. Patent & Trademark Office: "PDL1-pHLIP, a preparation method of the PDL1-pHLIP, and an application of the PDL1-pHLIP in treatment of autoimmune diseases are provided. A fusion peptide is prepared by binding a pH low insertion peptide and an extracellular domain of PDL1. The pH low insertion peptide may be inserted onto a cell membrane of a focus tissue in an acid environment; the PDL1 bound to the pH low insertion peptide is subjected t...